Linked Life Data

15958593

Source:http://linkedlifedata.com/resource/pubmed/id/15958593

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2005-6-16
pubmed:abstractText
Blocking estrogen receptors with antiestrogens and blocking estrogen synthesis with aromatase inhibitors are two strategies currently being used for reducing the effect of estrogen in postmenopausal estrogen receptor-positive breast cancer patients. To optimize these treatment strategies, we have investigated whether tumor progression can be delayed by combining the pure antiestrogen fulvestrant with the nonsteroidal aromatase inhibitor letrozole. These studies were done in ovariectomized, athymic mice bearing tumors of estrogen receptor-positive human breast cancer cells stably transfected with the aromatase gene (MCF-7Ca). Groups of mice with equivalent tumor volumes were injected s.c. daily with vehicle (control; n = 6), fulvestrant (1 mg/d; n = 7), letrozole (10 microg/d; n = 18), or letrozole (10 microg/d) plus fulvestrant (1 mg/d; n = 5). All treatments were effective in suppressing tumor growth compared with controls (P < 0.001). Tumor volumes of the fulvestrant-treated group had doubled in 10 weeks. After 19 weeks of letrozole (10 microg/d) treatment when tumors had nearly doubled in volume, mice (n = 18) were assigned to second-line therapy with letrozole (100 microg/d; n = 6), tamoxifen (100 microg/d; n = 6), or remained on letrozole treatment (10 microg/d; n = 6). However, tumors continued to increase in volume in these groups. Tumors of animals treated with the combination of letrozole plus Faslodex regressed over 29 weeks of treatment by 45%. Thus, the combination of letrozole plus fulvestrant was more effective in suppressing tumor growth than either letrozole or fulvestrant alone or sequential therapies with tamoxifen or a higher dose of letrozole (100 microg/d).
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0008-5472
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
65
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5439-44
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:15958593-Animals, pubmed-meshheading:15958593-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15958593-Aromatase Inhibitors, pubmed-meshheading:15958593-Breast Neoplasms, pubmed-meshheading:15958593-Cell Growth Processes, pubmed-meshheading:15958593-Cell Line, Tumor, pubmed-meshheading:15958593-Dose-Response Relationship, Drug, pubmed-meshheading:15958593-Drug Synergism, pubmed-meshheading:15958593-Estradiol, pubmed-meshheading:15958593-Estrogen Receptor Modulators, pubmed-meshheading:15958593-Female, pubmed-meshheading:15958593-Humans, pubmed-meshheading:15958593-Mice, pubmed-meshheading:15958593-Mice, Inbred BALB C, pubmed-meshheading:15958593-Mice, Nude, pubmed-meshheading:15958593-Nitriles, pubmed-meshheading:15958593-Postmenopause, pubmed-meshheading:15958593-Tamoxifen, pubmed-meshheading:15958593-Triazoles, pubmed-meshheading:15958593-Xenograft Model Antitumor Assays
pubmed:year
2005
pubmed:articleTitle
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
pubmed:affiliation
Department of Pharmacology and Experimental Therapeutics, School of Medicine, University of Maryland, Baltimore, Maryland, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, N.I.H., Extramural